Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07070440 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 100 → 180 participants Secondary endpoints revised (7) · Eligibility criteria expanded, about 3 wordsv3 Show 2 more changesShow less
    • Secondary endpoints revised (7)
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jul 2025 to Jul 16, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Jul 2025 to Jul 16, 2025
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate safety and antitumor activity of DZD6008 combination therapy in patients with advanced Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutations.
Trial Details
NCT Number NCT07070440
Lead Sponsor Dizal Pharmaceuticals
Conditions Non Small Cell Lung Cancer
Enrollment 180 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov